COVID-19: Implications for Patients With CLL

Download All
Keep abreast of ongoing developments in providing optimal care for patients with CLL during COVID-19 and evolving research into countering COVID-19–associated inflammatory cytokine production! Get expert perspectives on emerging data with focused commentaries, an FAQ module, and a “living” slideset regularly updated to incorporate the most important clinical findings on CLL and COVID-19.
Jacqueline Barrientos, MD, MS
Nicole Lamanna, MD
John Pagel Headshot
John Pagel, MD, PhD
person default
Jacob D. Soumerai, MD

FAQ Module

Read expert answers to key questions asked by clinicians during a series of live Webinars focused on the interface of CLL and the COVID-19 pandemic, including COVID-19 outcomes in patients with CLL, minimizing COVID-19 risk, selecting CLL treatments during the pandemic, BTK and PI3K inhibition in patients with COVID-19, and considerations for when a COVID-19 vaccine is available.

Jacqueline Barrientos, MD, MS Nicole Lamanna, MD John Pagel Headshot John Pagel, MD, PhD person default Jacob D. Soumerai, MD Released: December 9, 2020
Provided by Clinical Care Options, LLC.

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by an educational grant from
AstraZeneca

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue